Related references
Note: Only part of the references are listed.PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials
Filip Janku et al.
CANCER RESEARCH (2013)
Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma
Brian A. Walker et al.
BLOOD (2012)
Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1
Christoph J. Heuck et al.
CLINICAL CANCER RESEARCH (2012)
Targeting the PI3K signaling pathway in cancer therapy
Chandra Bartholomeusz et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Yuan Xiao Zhu et al.
BLOOD (2011)
Initial genome sequencing and analysis of multiple myeloma
Michael A. Chapman et al.
NATURE (2011)
Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma
Jonathan J. Keats et al.
CANCER CELL (2007)
A heterodimeric complex that promotes the assembly of mammalian 20S proteasomes
Y Hirano et al.
NATURE (2005)
Variations of the human glucocorticoid receptor gene (NR3C1): Pathological and in vitro mutations.and polymorphisms
PJ Bray et al.
HUMAN MUTATION (2003)
Share Paper
